Idelalisib is able to interfere with integrin-mediated adhesion, in particular with VLA-4 on CLL cells and VCAM-1 on EC/BMSC, causing lymph node shrinkage with a redistribution of CLL into the blood. This evidence concerns the gene VCAM1 and B-cell chronic lymphocytic leukemia.